Bristol-Myers Squibb Company BMY and Simcere Pharmaceutical Group
SCR, a leading pharmaceutical company in China, today announced that
the companies have expanded their strategic relationship formed in 2010. The
companies have agreed to collaborate in China on the development and
commercialization of the subcutaneous (SC) formulation of Bristol-Myers
Squibb's biologic medicine, Orencia® (abatacept), for the treatment of
rheumatoid arthritis. Orencia SC is already on the market for the treatment of
rheumatoid arthritis in the U.S., Europe and Japan.
Under the terms of the agreement, Simcere will perform and fund all
development and regulatory activities required to obtain market approval for
Orencia SC in China, based on a pre-agreed development plan. The companies
will share responsibility for commercializing Orencia, and will share profits
and losses related to Orencia SC in China. Financial terms were not
disclosed.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in